Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.
暂无分享,去创建一个
[1] S. Larson,et al. Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[2] Zheng Fu,et al. Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus , 2007, Journal of Nuclear Medicine.
[3] Myeong-Jin Kim,et al. Comparison of CT and 18F-FDG PET for Detecting Peritoneal Metastasis on the Preoperative Evaluation for Gastric Carcinoma , 2006, Korean journal of radiology.
[4] D. Cobben,et al. Prognostic value of the standardized uptake value in esophageal cancer. , 2005, AJR. American journal of roentgenology.
[5] O. Sabri,et al. Fluorine-18 fluorodeoxyglucose positron mission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases , 1997, European Journal of Nuclear Medicine.
[6] M. Kadoya,et al. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression , 2006, Annals of nuclear medicine.
[7] 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response , 2006, British Journal of Cancer.
[8] Philip Smith,et al. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[9] G. Glatting,et al. Values and Limitations of 18F-Fluorodeoxyglucose–Positron-Emission Tomography with Preoperative Evaluation of Patients with Pancreatic Masses , 2000, Pancreas.
[10] H. Fukuda,et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] W. Chapman,et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. , 1999, Annals of surgery.
[12] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Sugino,et al. Expression of glucose transporter‐1 in human gastric carcinoma , 2001, Cancer.
[14] H. Sakahara,et al. Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.
[15] Y. Bang,et al. The role of PET/CT in detection of gastric cancer recurrence , 2009, BMC Cancer.
[16] J. Luketich,et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. , 1999, The Annals of thoracic surgery.
[17] P. Bartenstein,et al. Positron Emission Tomography for Staging Esophageal Cancer: Does It Lead to a Different Therapeutic Approach? , 2003, World Journal of Surgery.
[18] S. Fujita,et al. Role of gastric distention with additional water in differentiating locally advanced gastric carcinomas from physiological uptake in the stomach on 18F-fluoro-2-deoxy-D-glucose PET , 2009, Nuclear medicine communications.
[19] J. Pruim,et al. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? , 2001, European Journal of Nuclear Medicine.
[20] Dong Soo Lee,et al. Cancer screening using 18F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report , 2009, Annals of nuclear medicine.
[21] A. Zauber,et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. , 1991, Radiology.
[22] N. Holalkere,et al. Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters , 2009, Abdominal Imaging.
[23] P. Shreve. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease , 1998, European Journal of Nuclear Medicine.
[24] Hanna El Balaa,et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. , 2005, International journal of radiation oncology, biology, physics.
[25] R. Fujita,et al. Significance of 18F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography , 2009, Annals of nuclear medicine.
[26] Zhen Wang,et al. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review , 2011, BMC gastroenterology.
[27] P. Veit-Haibach,et al. Contrast-Enhanced 18F-FDG PET/CT: 1-Stop-Shop Imaging for Assessing the Resectability of Pancreatic Cancer , 2008, Journal of Nuclear Medicine.
[28] A. Patriti,et al. [Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC]. , 2007, Annali italiani di chirurgia.
[29] G. Fakhri,et al. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation , 2007, Annals of nuclear medicine.
[30] J. Choi,et al. Detecting recurrence of gastric cancer: the value of FDG PET/CT , 2009, Abdominal Imaging.
[31] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Malafa,et al. PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms , 2008, Annals of Surgical Oncology.
[33] D. Visvikis,et al. Use of Positron Emission Tomography in Surgery Follow-Up of Esophageal Cancer , 2009, Journal of Gastrointestinal Surgery.
[34] Jinming Yu,et al. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. , 2009, European journal of radiology.
[35] Y. Nishiyama,et al. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[36] R. Boellaard,et al. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer , 2008, Endoscopy.
[37] A. Shields,et al. F-Fluorodeoxyglucose Positron Emission Tomography to Monitor Clinical Outcomes in Patients Treated With Neoadjuvant Chemo-Radiotherapy for Locally Advanced Pancreatic Cancer , 2010 .
[38] H. Katoh,et al. Evaluation of 18F-2-deoxy-2-fluoro-d-glucose Positron Emission Tomography for Gastric Cancer , 2004, World Journal of Surgery.
[39] H. Kuwano,et al. F-fluorodeoxyglucose Positron Emission Tomography to Predict Survival in Patients With Operable Esophageal Cancer , 2009 .
[40] R. Yamada,et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions , 2001, Annals of nuclear medicine.
[41] H. Amthauer,et al. Detection of Recurrent Pancreatic Cancer: Comparison of FDG-PET with CT/MRI , 2005, Pancreatology.
[42] P. Dupont,et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] H. Furukawa,et al. Is PET-CT suitable for predicting lymph node status for gastric cancer? , 2008, Hepato-gastroenterology.
[44] K. Kang,et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[45] H. Kwon,et al. Early detection of recurrence after endoscopic treatment for early gastric cancer , 2009, Scandinavian journal of gastroenterology.
[46] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.
[47] Karin Haustermans,et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[48] Lin Chen,et al. The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies , 2004, Nuclear medicine communications.
[49] A. Alavi,et al. Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET. , 2005, Clinical nuclear medicine.
[50] S. Larson,et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. , 2006 .
[51] M. Mori,et al. Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era? , 2008, Journal of Gastrointestinal Surgery.
[52] Yo-Han Cho,et al. Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.
[53] V. Rusch,et al. Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[54] H. Kuwano,et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma , 2002, Cancer.
[55] H. Groen,et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] M. Schwaiger,et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] K. Sugimura,et al. Performance of Integrated FDG-PET/Contrast-enhanced CT in the Diagnosis of Recurrent Pancreatic Cancer: Comparison with Integrated FDG-PET/Non-contrast-enhanced CT and Enhanced CT , 2010, Molecular Imaging and Biology.
[58] B. Loo,et al. Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[59] G. Glatting,et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[60] M. Sasaki,et al. An analysis of the physiological FDG uptake pattern in the stomach , 2003, Annals of nuclear medicine.
[61] A. Maurer,et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. , 2007, International journal of radiation oncology, biology, physics.
[62] S. Fanti,et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab , 2007, Gastric Cancer.
[63] H. Shirato,et al. Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological findings , 2009, International Journal of Clinical Oncology.
[64] Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy , 2007, British Journal of Cancer.
[65] A. Alavi,et al. Radiation-induced esophagitis on FDG PET imaging. , 2003, Clinical nuclear medicine.
[66] Woo Jin Hyung,et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography , 2005, Cancer.
[67] J. Ajani,et al. Laparoscopic staging for gastric cancer. , 1996, Surgery.
[68] A. Maes,et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[69] M. Gonen,et al. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction , 2008, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association.
[70] A. Dirksen,et al. Preoperative staging of lung cancer with combined PET-CT. , 2009, The New England journal of medicine.
[71] Fons Bongaerts,et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[72] F. Chierichetti,et al. 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma , 2003, Journal of Gastrointestinal Surgery.
[73] L. Mortelmans,et al. Histopathologic Validation of Lymph Node Staging With FDG-PET Scan in Cancer of the Esophagus and Gastroesophageal Junction: A Prospective Study Based on Primary Surgery With Extensive Lymphadenectomy , 2000, Annals of surgery.
[74] M. Schwaiger,et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[75] David Binns,et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[76] R. Kuzo,et al. F-18 FDG uptake in benign esophageal disease. , 1999, Clinical nuclear medicine.
[77] T. Mattfeldt,et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[78] K. Hirakawa,et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. , 2001, International journal of oncology.
[79] M. Schwaiger,et al. Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis , 2007, Journal of Nuclear Medicine.
[80] H. Amthauer,et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[81] Y. Yonekura,et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. , 1995, Radiology.
[82] T. Shiga,et al. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. , 2009, Internal medicine.
[83] H. Minn,et al. Adenocarcinoma of the Esophagus and the Esophagogastric Junction: Positron Emission Tomography Improves Staging and Prediction of Survival in Distant but Not in Locoregional Disease , 2004, Journal of Gastrointestinal Surgery.
[84] J. Ibdah,et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. , 2008, World journal of gastroenterology.
[85] J. Lee,et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[86] H. Isozaki,et al. Usefulness of preoperative FDG-PET for detection of gastric cancer , 2006, Gastric Cancer.
[87] Wolfgang A Weber,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] T. Saga,et al. Positron emission tomography for the diagnosis and management of patients with gastrointestinal malignancies. , 2008, Gastrointestinal endoscopy clinics of North America.
[89] H. Zhuang,et al. Gastric Distension by Ingesting Food Is Useful in the Evaluation of Primary Gastric Cancer by FDG PET , 2007, Clinical nuclear medicine.
[90] A. Alavi,et al. Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. , 2005, Clinical nuclear medicine.
[91] E. Kuipers,et al. Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis , 2007, British Journal of Cancer.
[92] H. Baba,et al. The Relationship between the Glucose Transporter Type 1 Expression and 18F-Fluorodeoxyglucose Uptake in Esophageal Squamous Cell Carcinoma , 2009, Oncology.
[93] Wolfgang A Weber,et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.
[94] Johannes A Langendijk,et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[95] S S Gambhir,et al. A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[96] Shu-qi Wu,et al. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis , 2009, European journal of gastroenterology & hepatology.
[97] M. Brennan,et al. Laparoscopy in the management of gastric adenocarcinoma. , 1997, Annals of surgery.
[98] V. Lowe,et al. Comparison of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasound in the Initial Staging of Patients with Esophageal Cancer , 2005, Molecular Imaging and Biology.
[99] N. Kosaka,et al. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. , 1999, Cancer.
[100] L. Mortelmans,et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. , 2000, The Journal of thoracic and cardiovascular surgery.
[101] T. Nishimura,et al. FDG-PET in a case of multiple bone metastases of gastric cancer , 2005, Annals of nuclear medicine.
[102] Byung-Tae Kim,et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. , 2003, Radiology.
[103] J. Lee,et al. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. , 2005, Journal of Nuclear Medicine.
[104] G. Patterson,et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. , 1997, The Annals of thoracic surgery.
[105] Tom Stargardt,et al. Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches , 2010, Journal of Nuclear Medicine Technology.
[106] J. Takita,et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma , 2005, Cancer.
[107] P. Conti,et al. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. , 2003, Clinical radiology.
[108] S. Reske,et al. Detection of liver metastases from pancreatic cancer using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[109] M. Shah,et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. , 2009, Journal of the American College of Surgeons.
[110] M. Senda,et al. Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study. , 2009, Japanese Journal of Clinical Oncology.
[111] P. Laurén,et al. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.
[112] J. Wesseling,et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.